Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

UTHR opened at $316.93 on Friday. The company has a market capitalization of $14.06 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 4.77 and a beta of 0.49. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $273.16 and a 200-day moving average price of $243.58. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $321.80.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period last year, the company earned $4.86 earnings per share. Equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC lifted its stake in United Therapeutics by 13,769.2% during the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after purchasing an additional 8,950 shares during the last quarter. DekaBank Deutsche Girozentrale grew its position in United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after acquiring an additional 33,338 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after acquiring an additional 23,532 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of United Therapeutics by 90.3% in the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after acquiring an additional 26,325 shares during the last quarter. Finally, Duality Advisers LP boosted its stake in shares of United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 5,622 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. Oppenheimer increased their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Wells Fargo & Company raised their price objective on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 20th. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, May 2nd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $312.22.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.